- Home
- XRTX vs MEHA Comparison
XRTX vs MEHA Comparison
Compare XRTX & MEHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XRTX
- MEHA
- Stock Information
- Founded
- XRTX 2011
- MEHA 2020
- Country
- XRTX Canada
- MEHA United States
- Employees
- XRTX N/A
- MEHA N/A
- Industry
- XRTX Pharmaceuticals and Biotechnology
- MEHA Medicinal Chemicals and Botanical Products
- Sector
- XRTX Health Care
- MEHA Health Care
- Exchange
- XRTX Nasdaq
- MEHA Nasdaq
- Market Cap
- XRTX 4.4M
- MEHA 4.8M
- IPO Year
- XRTX N/A
- MEHA N/A
- Fundamental
- Price
- XRTX $0.55
- MEHA $0.42
- Analyst Decision
- XRTX
- MEHA
- Analyst Count
- XRTX 0
- MEHA 0
- Target Price
- XRTX N/A
- MEHA N/A
- AVG Volume (30 Days)
- XRTX 491.1K
- MEHA 4.6M
- Earning Date
- XRTX 11-14-2025
- MEHA 01-01-0001
- Dividend Yield
- XRTX N/A
- MEHA N/A
- EPS Growth
- XRTX N/A
- MEHA N/A
- EPS
- XRTX N/A
- MEHA N/A
- Revenue
- XRTX N/A
- MEHA $6,498,798.00
- Revenue This Year
- XRTX N/A
- MEHA N/A
- Revenue Next Year
- XRTX N/A
- MEHA N/A
- P/E Ratio
- XRTX N/A
- MEHA N/A
- Revenue Growth
- XRTX N/A
- MEHA N/A
- 52 Week Low
- XRTX $0.53
- MEHA $0.37
- 52 Week High
- XRTX $1.79
- MEHA $8.00
- Technical
- Relative Strength Index (RSI)
- XRTX 34.56
- MEHA N/A
- Support Level
- XRTX $0.54
- MEHA N/A
- Resistance Level
- XRTX $0.61
- MEHA N/A
- Average True Range (ATR)
- XRTX 0.05
- MEHA 0.00
- MACD
- XRTX -0.00
- MEHA 0.00
- Stochastic Oscillator
- XRTX 6.28
- MEHA 0.00
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.